K. Wollschlaeger

Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

Philipp Harter, Andreas du Bois, Maik Hahmann et al. · Annals of Surgical Oncology · 2006 · 422 citations

Medicine, Oncology, Surgery +16

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

Rongyu Zang, Philipp Harter, D. S. et al. · British Journal of Cancer · 2011 · 136 citations · Full text

Medicine, Oncology, Surgery +17

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

Klaus Baumann, Andreas du Bois, Werner Meier et al. · Annals of Oncology · 2012 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study

Fabian Trillsch, Sven� Mahner, Linn Woelber et al. · Annals of Oncology · 2014 · 75 citations · Full text

Medicine, Gynecology, Oncology +15

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR

Jacobus Pfisterer, Andreas du Bois, Jalid Sehouli et al. · Annals of Oncology · 2006 · 66 citations

Medicine, Gynecology, Oncology +14